Prudential Financial’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-13,266
Closed -$998K 2766
2022
Q2
$998K Buy
+13,266
New +$590K ﹤0.01% 1787
2022
Q1
Sell
-4,532
Closed -$201K 2723
2021
Q4
$201K Sell
4,532
-22,675
-83% -$1.01M ﹤0.01% 2550
2021
Q3
$1.87M Sell
27,207
-26,386
-49% -$1.88M ﹤0.01% 1495
2021
Q2
$4.18M Buy
53,593
+8,497
+19% +$628K 0.01% 1105
2021
Q1
$4.27M Sell
45,096
-162
-0.4% -$19.3K 0.01% 1093
2020
Q4
$5.51M Buy
45,258
+24,180
+115% +$2.65M 0.01% 964
2020
Q3
$1.84M Buy
21,078
+1,347
+7% +$93.8K ﹤0.01% 1359
2020
Q2
$1.27M Sell
19,731
-514
-3% -$29.7K ﹤0.01% 1538
2020
Q1
$904K Buy
20,245
+410
+2% +$21.8K ﹤0.01% 1723
2019
Q4
$1.24M Sell
19,835
-1,025
-5% -$48.8K ﹤0.01% 1784
2019
Q3
$784K Buy
+20,860
New +$908K ﹤0.01% 1927

Prudential Financial's TPTX Position: Q3 2022 in Review

Prudential Financial sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 13,266 shares — an estimated $998K sold.

Prudential Financial first reported a position in TPTX in Q3 2019 and held it in 11 quarters. The position peaked at $5.51M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Prudential Financial reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Prudential Financial sold 13,266 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $998K.
  • Prudential Financial first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Prudential Financial's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.51M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Prudential Financial's 13F filing for Q3 2022, filed 4 Nov 2022.